Summary Renewable natural gas can be produced from raw biogas, a product of the anaerobic decomposition of organic material, by upgrading its CO2 content (25‐50%) via thermocatalytic hydrogenation (CO2 methanation). The H2 needed for this reaction can be generated by water electrolysis powered by carbon emission‐free energy sources such as renewable or nuclear power, or using surplus electricity. Herein, after briefly outlining some aspects of biogas production at dairy farms and highlighting recent developments in the design of methanation systems, a case study on the renewable natural gas generation is presented. The performance of a system for renewable natural gas generation from a 2000‐head dairy farm livestock manure is evaluated and assessed for its economic potential. The project is predicted to generate revenue through the sale of energy and carbon credits with the payback period of 5 years, with a subsidized energy price.
Contention exists within the field of oncology with regards to gastroesophageal junction (GEJ) tumors, as in the past, they have been classified as gastric cancer, esophageal cancer, or a combination of both. Misclassifications of GEJ tumors ultimately influence treatment options, which may be rendered ineffective if treating for the wrong cancer attributes. It has been suggested that misclassification rates were as high as 45%, which is greater than reported for junctional cancer occurrences. Here, we aimed to use the methylation profiles of GEJ tumors to improve classifications of GEJ tumors. Four cohorts of DNA methylation profiles, containing ~27,000 (27k) methylation sites per sample, were collected from the Gene Expression Omnibus and The Cancer Genome Atlas. Tumor samples were assigned into discovery (nEC = 185, nGC = 395; EC, esophageal cancer; GC gastric cancer) and validation (nEC = 179, nGC = 369) sets. The optimized Multi-Survival Screening (MSS) algorithm was used to identify methylation biomarkers capable of distinguishing GEJ tumors. Three methylation signatures were identified: They were associated with protein binding, gene expression, and cellular component organization cellular processes, and achieved precision and recall rates of 94.7% and 99.2%, 97.6% and 96.8%, and 96.8% and 97.6%, respectively, in the validation dataset. Interestingly, the methylation sites of the signatures were very close (i.e., 170–270 base pairs) to their downstream transcription start sites (TSSs), suggesting that the methylations near TSSs play much more important roles in tumorigenesis. Here we presented the first set of methylation signatures with a higher predictive power for characterizing gastroesophageal tumors. Thus, they could improve the diagnosis and treatment of gastroesophageal tumors.
As we all know that water is the most precious compound found in nature.It covers about 71% of the earth surface. About 97.3% of water is contained in the great oceans that are saline and 2.14% is held in icecaps glaciers and in the poles, which are not useful. The remaining 0.56% are found on earth which are useful for general purpose. Out of which Groundwater is one of the purest form of water available on this earth. It has been estimated that approximately one third of the world’s population use groundwater for drinking. This project is done in knowledge to get the analysis of various physico- chemical parameters such as pH, Turbidity, TDS, Total Alkalinity, Total Hardness, Chloride and Dissolved Oxygen of Gorakhpur city in view to ensure the groundwater to be fit for drinking purpose or not . About 20 samples were collected from India Mark-II Hand Pumps and Shallow Hand Pumps of various locations of Gorakhpur city and tested. After the analysis of various physico - chemical parameters of the samples collected , the groundwater found to be within permissible according to BIS 10500 – 2012.
Clinical management of papillary thyroid cancer depends on estimations of prognosis. Standard care, which relies on prognostication based on clinicopathologic features, is inaccurate. We applied a machine learning algorithm (HighLifeR) to 502 cases annotated by The Cancer Genome Atlas Project to derive an accurate molecular prognostic classifier. Unsupervised analysis of the 82 genes that were most closely associated with recurrence after surgery enabled identification of three unique molecular subtypes. One subtype had a high recurrence rate, an immunosuppressed microenvironment, and enrichment of the EZH2-HOTAIR pathway. Two other unique molecular subtypes with a lower rate of recurrence were identified, including one subtype with a paucity of BRAFV600E mutations and a high rate of RAS mutations. The genomic risk classifier, in addition to tumor size and lymph node status, enabled effective prognostication that outperformed the American Thyroid Association clinical risk stratification. The genomic classifier we derived can potentially be applied preoperatively to direct clinical decision-making. Distinct biological features of molecular subtypes also have implications regarding sensitivity to radioactive iodine, EZH2 inhibitors, and immune checkpoint inhibitors.
Background: Lung cancer is the leading cause of cancer death worldwide, with LUSC accounting for a third of cases. Stage I and II LUSC is typically treated with resection, and decisions related to adjuvant chemotherapy are related to recurrence risk, which is a function of stage. However, disease stage does not fully capture tumor biology, which may be a more important determinant of recurrence risk. Our objective was to identify biologically significant molecular subgroups of LUSC that more accurately reflect recurrence risk. Methods: Transcriptomic data for resected stage I/II LUSC were obtained from The Cancer Genome Atlas (TCGA). A training set consisting of patients who underwent resection without adjuvant chemotherapy or radiotherapy was used for discovery (N=161). A proprietary machine learning algorithm (HighLifeR™) was used to identify the genes most associated with disease-free survival (DFS). Molecular subgroups were identified by unsupervised clustering of prognostic genes. Functional differences between molecular subgroups were identified by gene set enrichment analysis (GSEA) and Ingenuity Pathway Analysis (IPA). Results: HighLifeR™ identified 60 highly prognostic genes. Two molecular subgroups were identified with significantly different median DFS: a high-risk group with 59.300 months and hazard ratio of 11.551, and a low-risk group that did not reach 50% DFS (log-rank p = 1.96 x 10-5). These subgroups did not differ in age, sex, race, smoking status, or overall stage (p > 0.05). Importantly, univariate and multivariate Cox regression analysis showed that the molecular subgroups outperformed clinical stage in predicting DFS. The molecular subgroups were biologically distinct. On GSEA, the high-risk group was significantly enriched in genes involved in mitotic spindle assembly (NES=1.94, p<0.001); TGFα signaling and PI3K/AKT/mTOR signaling were modestly enriched. IPA pathway analysis demonstrated significant enrichment of numerous pathways linked to neuronal growth and signaling (eg: CREB signaling, S100 signaling, pathways in myelination and synaptogenesis), as well as TGFα signaling and AMPK signaling (all p<0.001). Conclusions: Our prognostic transcriptomic signature identified two biologically distinct molecular subgroups of LUSC. Molecular subgroup classification was more predictive of DFS in stage I and II LUSC than any other clinical or pathological variable. If further validation confirms this, then this biomarker may form the basis of a diagnostic test that helps inform which patients could be considered for adjuvant chemotherapy. Citation Format: Ashar Siddiqui, Cynthia Stretch, Farshad Farshidfar, Oliver F. Bathe. Clinically and biologically distinct molecular subtypes of lung squamous cell carcinoma (LUSC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2049.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.